Dyne Therapeutics, Inc. [Rocket]

Overview

Dyne Therapeutics, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
08/03/2023	8-K	Quarterly results
08/03/2023	10-Q	Quarterly Report for the period ended June 30, 2023
06/15/2023	144	Form 144 - Report of proposed sale of securities:
06/15/2023	4	Scalzo Richard William (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
06/12/2023	144	Form 144 - Report of proposed sale of securities:
06/12/2023	4	Brumm Joshua T (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
06/09/2023	144	Form 144 - Report of proposed sale of securities:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18
Revenues	0.0	142.8	0.0	121.3	0.0	0.0	0.0
Revenue growth		17.7%
Cost of goods sold	0.0	171.0	0.0	150.0	0.0	0.0	0.0
Gross profit	0.0	-28.2	0.0	-28.7	0.0	0.0	0.0
Gross margin		-19.8%		-23.7%
Selling, general and administrative	171.0		150.0		58.6
Research and development						11.0	4.3
General and administrative		28.2		28.7		2.8	0.5
EBIT	0.0	-171.0	0.0	-150.0	0.0	-13.8	-4.8
EBIT margin		-119.8%		-123.7%
Pre-tax income	-168.1	-168.1	-149.3	-149.3	-59.4	-14.9	-4.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-168.1	-168.1	-149.3	-149.3	-59.4	-14.9	-4.8
Net margin		-117.7%		-123.1%

Diluted EPS	($3.23)	($3.23)	($2.93)	($2.93)	($4.13)	($6.08)	($10.15)
Shares outstanding (diluted)	52.0	52.0	50.9	50.9	14.4	2.4	0.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.